Bioprojet UK Limited supplies and commercialises Bioprojet products across the United Kingdom and Ireland. The company began as Lincoln Medical, registered in the UK in 2000. Bioprojet Pharma acquired Lincoln Medical in 2014, and the company was formally rebranded as Bioprojet UK Limited in 2021.
Bioprojet is a pharmaceutical laboratory founded on a commitment to innovation in the service of health, headquartered in Paris, France. For over 30 years, we have been designing and developing medicines with patient needs at the core of our approach. Our strength lies in combining scientific expertise with a strong human commitment.
Visit our global website to find out more.
At Bioprojet, patient health is at the heart of our scientific commitment. We develop innovative and targeted therapeutic solutions designed to improve quality of life.
Bioprojet focuses on therapeutic areas with significant unmet needs, particularly sleep disorders (narcolepsy, excessive daytime sleepiness), gastroenterology, and allergy & immunology.
OSA
Obstructive Sleep Apnoea-Hypopnoea Syndrome (OSAHS) is characterized by the occurrence, during sleep, of abnormally frequent episodes of interrupted breathing (apnoeas) or significant reductions in airflow (hypopnoeas). These apnoea and hypopnoea episodes can cause hypoxemia (a drop in haemoglobin oxygen saturation) and micro-awakenings.
Excessive Daytime Sleepiness
OSAHS has a major impact on patients’ daily lives in terms of quality of life, health, and safety. It often results in excessive daytime sleepiness (EDS).
This is characterized by an irresistible tendency to fall asleep if the person is not stimulated. It can lead to attention, concentration, or alertness disorders that may affect patients’ professional and social activities.
Alertness disorders related to daytime sleepiness increase the risk of household accidents, workplace accidents, and road traffic accidents.
What is anaphylaxis?
Anaphylaxis is a severe systemic allergic reaction that can be life-threatening. It occurs rapidly after contact with an allergen such as :
What are the symptoms?
The reaction is often characterized by :
These symptoms, especially respiratory ones, can be worsened if there is an associated respiratory condition (such as asthma).
Narcolepsy
Narcolepsy is a long-term sleep disorder that affects the brain’s ability to control sleep and wakefulness. The underlying causes of narcolepsy involve the central nervous system, meaning it is classified as a neurological condition.
In the UK Narcolepsy affects 1 person in 2500, that’s estimated to be 30,000.¹
Common symptoms include:
Cataplexy is a symptom that sometimes, but not always occurs with narcolepsy. It involves sudden and involuntary muscle weakness which is typically triggered by strong emotions—such as laughter, excitement, surprise, or anger. Cataplexy attacks are brief, typically lasting a few seconds to a few minutes.
Not everyone with narcolepsy experiences cataplexy. When they do, the condition is often called “Narcolepsy Type 1.”
Narcolepsy is a lifelong condition and affects all aspects of daily life: personal, professional, social, and family. It is often accompanied by difficulties with concentration and learning.
1. Narcolepsy UK. https://www.narcolepsy.org.uk/about-narcolepsy/
For medical information, please contact
medicalinformation@jensongroup.com or Tel. 01271 334609
For all other enquiries, please contact
info@bioprojet.uk or Tel. 01722 742900
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Bioprojet UK Ltd on +44 (0) 1271 334609 or email: pvuk@bioprojet.uk
Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie
Adverse events should also be reported to Bioprojet Pharma on +353 (0)1686 9342 or email: pvie@bioprojet.uk